Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Authors

Hayman Salib MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

11-2024

Volume

144

Issue

1

Published In/Presented At

https://doi.org/10.1182/blood-2024-203880

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article